Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Section 3 of 6

Product information and disease description

301 evidence topics · 149 sources

Product description

Phase of product development

Regulatory status: Submission planned; U.S. accelerated approval application planned if the AMPLITUDE interim analysis, with data expected in early 2027, is positive
Launch

No evidence found.

Authorisation status in the European Union: not authorised
FieldQuoted record
Investigational medicinal product“VX-147 film-coated tablet”
Active substance“Inaxaplin”
Authorisation status“Not authorised”
Medicine status in the EU“No EU-wide authorisation listed”
Interim analysis endpoints: company wording from March 2022 to September 2025
FDA orphan drug and Fast Track designations

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Generic name, chemical name, and identifiers
FieldQuoted record
International nonproprietary name (Latin)“inaxaplinum”
International nonproprietary name (English)“inaxaplin”
Chemical name“3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]-N- [(3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl]propanamide”
Functional description“apolipoprotein L1 (APOL1) function inhibitor”
Molecular formula“C21H18F3N3O3”
CAS registry number“2446816-88-0”
INN list“Proposed INN: List 125”
Brand name

No evidence found.

Dosage forms and strengths
Commercial strengths and package sizes

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Indication expansion studied in AMPLIFIED: AMKD with modest proteinuria or with type 2 diabetes
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on Inaxaplin
Effects of Inaxaplin on other drugs
Dosing and administration
Dosage
Maximum daily dose, total dose, and treatment duration in the EU trial record
FieldQuoted record
Maximum daily dose“45 mg milligram(s)”
Maximum total dose“4860 mg milligram(s)”
Maximum duration of treatment“108 week(s)”
Administration
Access and distribution
Companion diagnostic

No evidence found.

Specialty pharmacy or distribution network

No evidence found.

Co-prescribed/Concomitant therapies
Effect of Inaxaplin on quality measures
Product-specific effect on quality measures

No evidence found.

Product comparison
APOL1-directed and other investigational therapies for AMKD: review table
MZE829 (Maze Therapeutics): oral dual-mechanism APOL1 inhibitor, phase 2 HORIZON interim results

“today announced positive topline data from the Phase 2 HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidney disease (AMKD).” (opens the source at this quote in a new tab)

“The HORIZON study is a Phase 2, open-label basket design trial that enrolled patients with broad AMKD carrying the APOL1 high risk genotype, including diabetic and non-diabetic patients and non-diabetic patients with severe focal segmental glomerulosclerosis (FSGS).” (opens the source at this quote in a new tab)

“For this topline analysis, 15 patients were enrolled in the HORIZON study and all were included in a safety and tolerability analysis. Twelve patients were evaluated for efficacy, i.e., uACR reduction, based on meeting the per protocol compliance threshold.” (opens the source at this quote in a new tab)

“Across all evaluated patients, a mean reduction in proteinuria from baseline of 35.6% was observed and 50% of patients achieved at least a 30% reduction in uACR.” (opens the source at this quote in a new tab)

“In FSGS patients, treatment with MZE829 led to a mean reduction in uACR of 61.8%. In patients with AMKD without diabetes, treatment with MZE829 resulted in a clinically meaningful mean reduction in uACR of 48.6%. In patients with AMKD with diabetes, five patients were evaluable per protocol for efficacy, with two patients achieving at least a 30% reduction in uACR.” (opens the source at this quote in a new tab)

“No serious adverse events (AEs) or severe treatment-related adverse events (TRAEs) were observed.” (opens the source at this quote in a new tab)

Place of product in therapy

Disease description

Definition and etiology
Genetic cause: G1 and G2 variants with a recessive two-risk-allele genotype
Phenotype spectrum: FSGS, hypertension-attributed kidney disease, HIVAN, COVAN, lupus nephritis, and sickle cell nephropathy
Second hits and modifiers: interferon, viral infection, and the p.N264K variant
Epidemiology
Incidence of APOL1-mediated kidney disease
Penetrance: lifetime risk of CKD, kidney failure, FSGS, and HIVAN among genotype carriers
Prevalence of APOL1-mediated kidney disease
United States: high-risk genotype frequency among Black Americans
West Africa and sub-Saharan Africa: high-risk genotype frequency
Company estimates: Vertex Pharmaceuticals statements of the affected population in the United States and Europe, 2024 to 2026
Natural history, survival, and mortality
Penetrance: lifetime risk of kidney failure with a high-risk genotype
Trajectory of eGFR decline in hypertension-attributed CKD
Mortality: death before kidney failure and all-cause mortality by genotype
Kidney transplantation: allograft survival with kidneys from high-risk genotype donors
Pathophysiology
Gain-of-function cation channel activity of the G1 and G2 variants
Interferon-induced APOL1 expression and second hits
Diagnosis
Living kidney donor evaluation
Clinical presentation - signs and symptoms
Cardiovascular signs: hypertension
Acute presentation: acute kidney injury and nephrotic syndrome with collapsing glomerulopathy
Long-term morbidity
Cardiovascular disease
Burden of APOL1-mediated kidney disease
Humanistic burden and health-related quality of life
Health-related quality of life, anxiety, and depression in 78 adults and 29 children with primary FSGS and their care-partners

“This study cross-sectionally surveyed patients with primary focal segmental glomerulosclerosis (FSGS) and their caregivers/care-partners, in terms of physical and mental health-related quality of life (HRQoL) and work productivity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“78 adults and 29 children/adolescents with FSGS, with their care-partners/caregivers, were included. The median ages of adults and children/adolescents with FSGS were 44.5 and 12.0 years, respectively; 74.4% and 58.6% were female. Mean physical and mental SF-12 scores for adult patients were 41.9 (SD: 12.1) and 44.8 (10.2), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Both SF-12 components for adult patients, the SF-12 mental component for care-partners, and all PedsQL item scores were worse compared to US general population estimates. Among adult patients, 28.2% reported at least moderate anxiety; 37.3% reported at least moderate depression. Compared to external controls, patients experienced significantly higher severity of anxiety (6.1 vs. 5.0) and depression (7.6 vs. 5.9; both p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients with FSGS and their care-partners experience impairments to mental/physical HRQoL and work productivity, underscoring the need for effective FSGS therapies and care-partner support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Economic burden and healthcare resource utilization
AMKD-specific health care resource utilization and cost studies

No evidence found.

Per person per year Medicare fee-for-service spending among older adults with CKD, by race and CKD stage
Economic impact of APOL1-mediated kidney disease on families
APOL1-specific family cost studies

No evidence found.

Economic impact of diagnostic testing
List price or Medicare payment rate for APOL1 genotyping

No evidence found.

Approaches to treatment

Current treatment options and standard of care
Renin-Angiotensin system inhibitors and blood pressure control
Sodium-Glucose cotransporter-2 inhibitors
Nonsteroidal mineralocorticoid receptor antagonists
Glucocorticoids and calcineurin inhibitors
Immunosuppression in primary and secondary FSGS: KDIGO 2021 glomerular diseases guideline

“Practice Point 6.2.1.1: Immunosuppression should not be used in adults with FSGS of undetermined cause (FSGS-UC), or in those with secondary FSGS.” (opens the source at this quote in a new tab)

“Recommendation 6.2.2.1: We recommend that high-dose oral glucocorticoids be used as the first-line immunosuppressive treatment for primary FSGS (1D).” (opens the source at this quote in a new tab)

“Practice Point 6.2.2.2: Initial high-dose glucocorticoids should be continued until complete remission is achieved, or as tolerated by patients up to a maximum of 16 weeks, whichever is earlier.” (opens the source at this quote in a new tab)

“Recommendation 6.3.1.1: For adults with steroid-resistant primary FSGS, we recommend that cyclosporine or tacrolimus be given for” (opens the source at this quote in a new tab)

“rather than continuing with glucocorticoid monotherapy or not treating (1C).” (opens the source at this quote in a new tab)

“Practice Point 6.3.3.1: Adults with steroid-resistant primary FSGS who respond to CNI treatment should receive CNIs for a minimum of 12 months to minimize the risk of relapses (Figure 55).” (opens the source at this quote in a new tab)

“There is no evidence or a priori rationale justifying the use of glucocorticoids or other immunosuppressive drugs in this population, and the potential for harm of such treatment is clear.” (opens the source at this quote in a new tab)

Dual endothelin angiotensin receptor antagonists
Sparsentan in participants with APOL1 high-risk genotypes: DUPLEX post hoc analysis
SubgroupSparsentan, time-averaged change from baseline in UPCR, % (95% CI)Irbesartan, time-averaged change from baseline in UPCR, % (95% CI)Relative change, % (95% CI)P value
APOL1 high-risk genotypes“−54.3 (−76.6 to −10.9)”View highlighted excerpt for this quote“−33.8 (−71.2 to 52.2)”View highlighted excerpt for this quote“−27.3 (−78.1 to 141.2)”View highlighted excerpt for this quote“0.57”View highlighted excerpt for this quote
Antiretroviral therapy for HIV-associated nephropathy
Dialysis
Kidney transplantation
Limitations of current therapies
Summary: limitations of current therapies

No therapy directed at APOL1-mediated kidney disease is approved; the KDIGO 2025 conference report states that there are “no established treatments or treatment recommendations for APOL1 kidney disease”, and a 2021 Delphi consensus agreed that “No specific treatment is currently available”. KDIGO guidelines recommend RAS blockade, blood pressure control, and dietary salt restriction for adults with FSGS, and an SGLT2 inhibitor for adults with CKD who meet the criteria the guideline specifies. In AASK, the primary kidney outcome occurred in 58.1% of participants with a high-risk genotype and 36.6% of those with a low-risk genotype (hazard ratio 1.88), with no interaction between APOL1 status and the randomized blood-pressure goal or antihypertensive drug. In the FSGS Clinical Trial, APOL1 genotype did not affect proteinuria response to cyclosporine or mycophenolate mofetil with dexamethasone, but participants with the high-risk genotype were more likely to progress to ESRD. In DUPLEX, sparsentan reduced proteinuria more than irbesartan without a significant difference in eGFR slope at 108 weeks, and the APOL1 high-risk subgroup comprised 14 participants. In a real-world cohort of 1,332 people with AMKD, 35.7% had a RAAS inhibitor fill or administration and 10.5% an SGLT2 inhibitor, and 45.7% had CKD stage 4 or 5.

Place in treatment, anticipated use, and care setting
Summary: anticipated place in therapy

Inaxaplin is investigational, and no labeled indication exists. The pivotal AMPLITUDE trial enrolls participants aged 10 to 65 years with two APOL1 variants (G1/G1, G2/G2, or G1/G2), a urine protein to creatinine ratio (UPCR) of 0.7 to less than 10 g/g, and an eGFR of 25 to less than 75 mL/min/1.73 m2, and excludes people with diabetes mellitus, a solid organ or bone marrow transplant, or another known cause of kidney disease. Inaxaplin is given as 45 mg once daily on top of standard of care. Vertex states that a positive AMPLITUDE interim analysis could form the basis for potential U.S. accelerated approval, and Vertex investor relations stated that AMPLITUDE could unlock a population of about 150,000 people in the U.S. and Europe. Vertex estimates approximately 100,000 further people with AMKD and comorbidities such as type 2 diabetes. The phase 2 AMPLIFIED study dosed 41 participants with modest proteinuria (cohort 1, n=23) or with type 2 diabetes (cohort 2, n=18), populations Vertex describes as not being studied in AMPLITUDE, and Fierce Biotech reported that an FDA label covering both cohorts would add about 100,000 people to the target population.

Use would depend on APOL1 genotyping. A Vertex-sponsored test describes a genetic test for two APOL1 risk variants as required for a definitive diagnosis of AMKD; trial eligibility used a Vertex-designated investigational assay, and the Vertex-sponsored Labcorp test states that it has not been cleared or approved by the FDA. A Delphi consensus panel agreed that nephrologists should counsel patients about APOL1 high-risk genotypes, order the test, and return results, and that if a treatment becomes available all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with counseling. The KDIGO Controversies Conference report states that when treatments become available, “patient access to nephrologists with experience or knowledge of APOL1 kidney disease will be paramount”. In a U.S. real-world cohort of 1,332 people with AMKD, 45.7% had CKD stage 4 or 5 at a mean age of 45.6 years, 35.7% had at least one administration or fill of a RAAS inhibitor, and 10.5% of an SGLT2 inhibitor.

Populations evaluated beyond the pivotal trial: AMPLIFIED
Heterogeneity of treatment effect
Summary: heterogeneity evidence for inaxaplin

The sources reviewed report no inaxaplin efficacy results stratified by APOL1 genotype. Of the 64 participants dosed in AMPLITUDE as of the 2024 abstract, 53.1% had the G1/G1, 37.5% the G1/G2, and 9.4% the G2/G2 genotype; efficacy results from that portion have not been published. The differences in response reported to date are by comorbidity and proteinuria level. In AMPLIFIED, the mean change in UACR at week 13 was -42.7% (95% CI -58.3% to -21.1%) in cohort 1 (modest proteinuria, most without diagnosed FSGS) and -17.3% (95% CI -36.3% to 7.2%) in cohort 2 (type 2 diabetes); the confidence intervals were generated post hoc, and the interval for cohort 2 includes no change. In the phase 2a study, the mean UPCR change was -47.7% in the 3 participants with nephrotic-range proteinuria and -47.5% in those with subnephrotic-range proteinuria, and 1 participant with 100% adherence had no reduction. In vitro, inaxaplin inhibited thallium flux in cells expressing G0, G1, and G2 APOL1; a 2026 abstract reports that inaxaplin partially reduced the cytotoxicity of full-length APOL1-G1 and did not rescue toxicity from a nuclear APOL1-G1 fragment produced by cathepsin S. For existing therapies, APOL1 genotype did not modify the effect of blood pressure target or ACE inhibitor treatment on CKD progression in AASK, and did not affect proteinuria response to cyclosporine or mycophenolate mofetil plus dexamethasone in the FSGS Clinical Trial; in AASK, strict blood pressure control was associated with 42% lower mortality in the high-risk genotype group only.

Care management intervention strategies
Delphi consensus: counseling before and after APOL1 testing

“Patients should have a clear understanding of the purpose of the APOL1 test and the potential implications of the result before the test is taken” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“When health care professionals discuss APOL1 testing with their patients, they should be honest and transparent about the current understanding of APOL1, take time to discuss APOL1 with patients, listen to their concerns, answer questions, and provide information sources that are balanced, easy to use and understand, and reliable” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After a patient with CKD is confirmed to have a high-risk APOL1 genotype, the clinician should:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Encourage the patient to participate in clinical trials for which they are eligible” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Inform the patient about other modifiable risk factors and renoprotective measures (lifestyle changes, BP control)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There is no established best practice for counseling patients about APOL1 testing; further research is required to define best practice” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Nephrology trainees need to be educated to be able to confidently deliver effective counseling to patients about APOL1 testing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Summary: expected outcomes

AMPLITUDE is designed to assess the effect of inaxaplin on kidney function and proteinuria. In the phase 2a study, proteinuria decreased by day 15 and continued to decrease through week 13. The phase 2a study reported a mean UPCR change of -47.6% (95% CI -60.0 to -31.3) at week 13; its authors cite data from nearly 30,000 participants in which a 30% albuminuria reduction corresponded to a 27% lower risk of a composite kidney endpoint, and state as a hypothesis to be tested that a longer treatment period may prevent or slow progression to end-stage kidney disease. The AMPLITUDE final analysis uses eGFR slope after two years as the primary efficacy endpoint and time to a composite of a sustained eGFR decline of 30% or more, end-stage kidney disease, or death as the secondary endpoint, assessed when approximately 187 composite outcomes have occurred. Across CKD trials, each 30% reduction in albuminuria was associated with a 27% lower hazard of the clinical endpoint (41 treatment comparisons, 29,979 participants) or a 19% lower hazard (48 trials, 85,681 participants), and a 0.75 mL/min/1.73 m2 per year greater treatment effect on total GFR slope with a 23.3% lower hazard. In FSGS, a partial remission defined as a 40% proteinuria reduction with proteinuria below 1.5 g/g was associated with less progression (hazard ratio 0.30 at month 8), and a 2025 review found that further work is needed to define a treatment effect short of complete remission as an endpoint. The only AMKD-specific analysis found, a preprint of 128 participants, estimated that a 50% reduction in UACR at 12 months was associated with a 28% lower risk of a kidney composite endpoint. The sources reviewed give no estimate of the delay in kidney failure expected with inaxaplin; Vertex states that people with AMKD reach kidney failure at a median age of 45 years.